GLAND Gland Pharma Q4 FY25 results (Jan–Mar 2025) and concall
Gland Pharma reported a quarter of mixed results, characterized by a flat full-year revenue performance but significant strategic progress in high-growth areas like GLP-1s and Biologics. While the base business remains highly profitable with 38% EBITDA margins, the Cenexi acquisition continues to be a drag on consolidated performance, though management expects an EBITDA-positive turnaround by Q3 FY26. The company is aggressively expanding its cartridge capacity to 140 million units to capture the burgeoning GLP-1 market.
You’re reading a preview. Opening the full call uses 1 concall credit.
Sign in to use your monthly call allowance.
What they filed
| Line item | Q2 FY25 | Q3 FY25 | Q4 FY25 |
|---|---|---|---|
| Revenue | 1,063 | 1,011 | 1,030 |
| EBITDA | 364 | 391 | 394 |
| Net profit | 282 | 295 | 290 |
How to read this
₹ crore, as filed. The percentage beside a figure is the change against the same quarter a year earlier — never the quarter before, which would make every seasonal business look like it collapses and booms each year.
Inve summary of a publicly available earnings call transcript; see how call summaries are prepared. Not investment advice.
